Pipeline moves forward—but the quarter’s loss looks heavier than expected

The financial result appears to have missed a thin consensus. Published estimates from two analysts pointed to an average Q2 loss of roughly $0.25 per share, while the filing reports a $24.1 million net loss for the quarter; the filing does not provide quarterly EPS. Collaboration revenue of $3.4 million was ahead of the roughly $2.0 million published revenue expectation, but revenue is not the main valuation driver for this clinical-stage biotech.

The pipeline delivered execution, not a major surprise. AKY-2519 produced first-in-human imaging and dosimetry data at ASCO, its prostate Phase 1b trial is enrolling, and regulators cleared the broader BActinium-2 basket trial. Those developments expand the program’s potential, but the ASCO data and the second-half-2026 basket-trial start were already part of the standing narrative rather than newly revealed evidence of efficacy. (AKY-2519 highlights) (Anticipated milestones for the next 12 months)

Cash removes near-term financing pressure but does not erase spending risk. Cash rose to $517.3 million after the January 2026 IPO and is expected to fund operations into 2029. That is a meaningful balance-sheet positive, but quarterly R&D rose 36% year over year and the net loss widened by $6.0 million as both clinical development and corporate infrastructure scaled. (Balance Sheet Data) (Condensed Consolidated Statement of Operations)

Net read: operationally on track, financially worse than expected. The company reaffirmed its development timetable and added no clinical setback, but those positives were largely anticipated. Against the market’s earnings benchmark, the heavier loss is the clearest new signal, making this a modest earnings miss rather than a clean execution beat.